8-K: BioAtla Reports Positive Clinical Trial Progress and First Quarter 2024 Financial Results

BioAtla announced its first quarter 2024 financial results and provided updates on its clinical programs, highlighting positive responses and manageable safety profiles for several key drug candidates.

Summary

• BioAtla reported its financial results for the first quarter of 2024, with a net loss of $23.2 million, compared to a net loss of $27.5 million for the same period in 2023.
• Research and development expenses decreased to $18.9 million from $21.7 million year-over-year, primarily due to the completion of pre-clinical development related to the Nectin-4 IND.
• General and administrative expenses also decreased to $5.6 million from $7.2 million year-over-year, mainly due to lower stock-based compensation and professional fees.
• The company's cash balance was $80.6 million as of March 31, 2024, which is expected to fund operations into the second half of 2025.
• BioAtla is progressing multiple clinical programs, including ozuriftamab vedotin, evalstotug, and mecbotamab vedotin, with plans to meet with the FDA regarding potential registrational trials for these candidates in the second half of 2024.
• Ozuriftamab vedotin showed a disease control rate of 86% in squamous cell carcinoma of the head and neck (SCCHN) patients, with 11 responses, including 5 confirmed and 1 complete response.
• Evalstotug is progressing well, with initial Phase 2 monotherapy data expected in the second quarter of 2024 and combination data with pembrolizumab expected in the second half of 2024.
• Mecbotamab vedotin has completed enrollment of the initial 20 patients in its Phase 2 study for undifferentiated pleomorphic sarcoma (UPS).
• The company anticipates a Phase 1 dose-escalation data readout for CAB-EpCAM x CAB-CD3 (BA3182) and potential initiation of a Phase 2 study in the second half of 2024.
• CAB-Nectin4-ADC (BA3361) received FDA IND clearance in May.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical progress, reduced expenses, and a cash runway into the second half of 2025. The company is moving towards potential registrational trials, which is a significant positive. However, the net loss and cash burn are still a concern.

Positives

• Multiple confirmed responses and a manageable safety profile were observed with ozuriftamab vedotin in SCCHN patients.
• Evalstotug is progressing well with meaningful antitumor activity observed at the 350 mg dose in combination with a PD-1 inhibitor.
• Mecbotamab vedotin has completed enrollment of the initial 20 patients in its Phase 2 study for UPS, showing encouraging compliance and manageable safety.
• The company has a strong cash position of $80.6 million, expected to fund operations into the second half of 2025.
• R&D expenses have decreased, indicating efficient resource allocation.
• The company has received FDA IND clearance for CAB-Nectin4-ADC (BA3361).

Negatives

• The company reported a net loss of $23.2 million for the first quarter of 2024.
• Net cash used in operating activities was $30.8 million for the quarter ended March 31, 2024, although this included $5 million in annual payments.
• Cash and cash equivalents decreased from $111.5 million at the end of 2023 to $80.6 million as of March 31, 2024.

Risks

• The company's clinical trials may face potential delays.
• There are uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints and regulatory approval dates.
• The company is dependent on the success of its CAB technology platform.
• The company relies on third parties for the manufacture and supply of its product candidates and to conduct clinical trials.
• There are potential adverse impacts due to any resurgence of COVID-19 and its variants.

Future Outlook

The company expects its current cash and cash equivalents to fund operations into the second half of 2025 and anticipates multiple important milestones throughout the remainder of the year, including FDA meetings for potential registrational trials and data readouts from ongoing clinical trials.

Management Comments

• We have had a productive start to the year, highlighted by positive clinical responses and a manageable safety profile observed with our CAB Phase 2 assets, including ozuriftamab vedotin and evalstotug.
• We are encouraged to see multiple responses with single agent ozuriftamab vedotin in a difficult to treat head and neck cancer population with a median of 3 prior lines of therapy and intend to schedule a meeting with the FDA later this year for a potential randomized registrational trial in this indication.
• We also continue to be encouraged with the early clinical profile being observed with evalstotug across multiple solid tumors and will be seeking FDA guidance on a potentially registrational study in first-line, metastatic or unresectable, BRAF-mutated melanoma in the second half of this year.
• As we near completion of several of our Phase 2 clinical trials, we remain well-positioned to deliver on multiple important milestones throughout the remainder of the year.

Industry Context

BioAtla's focus on Conditionally Active Biologics (CAB) technology positions it within the innovative segment of the biotechnology industry, aiming to develop more selective and less toxic antibody therapeutics. The company's progress in multiple clinical programs and its focus on securing FDA meetings for potential registrational trials align with the broader industry trend of advancing novel cancer treatments.

Comparison to Industry Standards

• BioAtla's ozuriftamab vedotin's 86% disease control rate in SCCHN is promising, especially considering the difficult-to-treat nature of this cancer and the median of 3 prior lines of therapy patients had received, which compares favorably to other treatments in this space.
• The company's focus on CAB technology, which aims to reduce systemic toxicity, is a key differentiator compared to traditional antibody therapies, such as those developed by companies like Seagen (now part of Pfizer) and ImmunoGen, which have faced challenges with toxicity.
• The development of evalstotug as a CAB anti-CTLA-4 antibody is aimed at improving the safety profile of CTLA-4 inhibitors, which have shown efficacy but are limited by immune-related adverse events, a common issue with drugs like ipilimumab (Yervoy) from Bristol Myers Squibb.
• BioAtla's approach to bispecific antibodies with BA3182, targeting EpCAM and CD3, is similar to other companies developing T-cell engagers, such as Amgen with Blincyto, but with the added benefit of CAB technology for tumor-specific activation.
• The development of CAB-Nectin4-ADC (BA3361) with improved stability and tumor-specific payload release is a competitive advantage in the ADC space, where companies like Daiichi Sankyo and AstraZeneca are also heavily invested.

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical trial results and the company's cash runway.
• Employees may be motivated by the progress of the company's clinical programs.
• Patients may benefit from the development of new cancer treatments.
• Creditors may be reassured by the company's financial stability.

Next Steps

• The company plans to meet with the FDA in the second half of 2024 for potential registrational trials for ozuriftamab vedotin in SCCHN, evalstotug in BRAF-mutated melanoma, and mecbotamab vedotin in UPS.
• The company will continue to enroll patients in ongoing clinical trials.
• The company will present Phase 1 evalstotug data at the upcoming ASCO Annual Meeting in June.
• The company will provide initial Phase 2 monotherapy data for evalstotug in the second quarter of 2024.
• The company will provide data readouts for evalstotug in combination with pembrolizumab in the second half of 2024.
• The company will provide a full dataset readout of the Phase 1 study for CAB-EpCAM x CAB-CD3 (BA3182) in the second half of 2024.
• The company will potentially initiate a Phase 2 study for CAB-EpCAM x CAB-CD3 (BA3182) in the second half of 2024.

Key Dates

Keywords

BioAtla, CAB, Ozuriftamab vedotin, Evalstotug, Mecbotamab vedotin, Antibody-drug conjugate, Clinical trials, FDA, Oncology, Biotechnology, Immunotherapy, SCCHN, Melanoma, UPS, Nectin4-ADC